Peptide

Thymopentin

Also known as

TP-5 · RKDVY · thymopoietin pentapeptide

Community talk. May contain inaccuracies. Not medical advice. Not a protocol. Not for human or animal use.

What it is

Identity	TP-5 is a defined synthetic five-amino-acid thymic peptide discussed for immune regulation. Thymalin, thymulin, Thymogen and Thymosin Alpha-1 are separate identities.

Notes

TP-5 is a defined five-part peptide. Its five amino acids, the building blocks of a peptide, are abbreviated RKDVY. It copies positions 32–36 of the larger thymus hormone thymopoietin. The immune research concerns T cells, which help coordinate immune responses; it does not establish a general wellness reset. Thymopentin: stability considerations and potency by various routes of administration (Official context · Accessed 2026-09-30) · Peptides for autoimmune disease (Community opinion · Accessed 2026-09-30)

Similar names do not mean the same substance. Thymalin, thymulin, Thymogen and Thymosin Alpha-1 are separate identities. In the purchaser discussion, commenters switch between several of those names. Their experiences, amounts and courses cannot automatically answer a question about TP-5. Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30)

Source context — Thymopentin: stability considerations and potency by various routes of administration: Publisher abstract/summary and references only; full paper subscription-gated. Human plasma stability is ex vivo, not PK in dosed humans. Animal route comparison does not determine a community human dose.

Source context — Peptides for autoimmune disease: Speculation and secondhand interpretation, not a TP-5 trial by this commenter. Unrelated medical misinformation elsewhere in the thread is not adopted. No amount or timing supplied. Exact post date not exposed in the opened view.

Source context — Seeking advice on dosing/efficacy of Thymopentin injections: Second-hand TP-5 efficacy story; no stated amount, route, personal post-use result, verified identity or independent follow-up. Deleted/moderated comments and unexpanded replies remain unavailable. D-mannose reports concern another substance.

What people notice

Reported hopes	A purchaser relays a physician's claim of fewer recurring UTIs after a course. An autoimmune commenter discusses immune regulation without having taken TP-5; neither provides a firsthand post-use benefit timeline.
Keep personal outcomes separate	The purchaser's own favorable UTI-prevention experience concerned D-mannose, not TP-5. No visible TP-5 success, nonresponse or adverse result from that purchaser was found.

Notes

Fewer recurring infections. The purchaser's interest began with a physician's reported experience with recurring urinary tract infections, or UTIs. This is an account of someone else's claimed benefit, not a demonstrated result from the person posting or evidence that TP-5 treats an active infection. Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30)

Immune regulation, rather than simply more activity. An autoimmune-thread commenter speculates that TP-5 may regulate an overactive response and cites an older study of myasthenia gravis, a condition causing muscle weakness. They do not report taking TP-5. Anti-aging also interests the purchaser, but neither discussion supplies a personal rejuvenation, energy or recovery result. Peptides for autoimmune disease (Community opinion · Accessed 2026-09-30) · Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30)

No firsthand onset estimate in these discussions. The purchaser asks what effects others feel; no visible personal post-use result answers that question. The autoimmune commenter discusses a possible use rather than a timed experience. Neither supplies a predictable response after hours, days or two weeks. Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30) · Peptides for autoimmune disease (Community opinion · Accessed 2026-09-30)

The purchaser's own favorable report was about D-mannose. Their personal UTI-prevention account concerned that separate supplement, with missed doses mentioned in the conversation. It must not be counted as a successful TP-5 trial. No visible TP-5 nonresponse or adverse experience from that purchaser was found either. Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30)

Doses people talk about

100–200 mcg every three days	One promotional table lists this per-use amount, 0.1–0.2 mg, without route, product, supporting source or outcome. It is a chart assertion, not a checked common dose.
Separate 50 mg chart	Older product-chart talk describes about 50 mg per injection daily or every other day, with product and exact route unresolved. This cannot be combined with the microgram chart into a useful dose range.
Historical-study claim	A reference site lists 50 mg subcutaneously three times weekly for HIV as unverified imported information. Disease-specific research claims are not firsthand wellness reports.

Notes

100–200 mcg per use, every three days: one promotional chart. PeptideBasicsDOTcom's Reddit table lists this amount, equivalent to 0.1–0.2 mg. It gives no TP-5 route, product, supporting source or personal outcome. This is a chart assertion, not a checked common dose or a daily total. Basic Peptide Dosing Protocols (Community guide · Accessed 2026-09-30)

About 50 mg per injection: older product-chart talk. The older chart account pairs this with daily or every-other-day injections. Its product and exact route are unresolved. The microgram chart has a different origin; this large numerical disagreement does not establish a useful dose range.

50 mg three times weekly: a circulated historical-study figure. Peptide Corpus lists this under-the-skin HIV schedule as unverified imported information. Its origin is a disease-specific research claim, not a firsthand wellness report. The site's intravenous rheumatoid-arthritis figure is a separate route and context. Thymopentin: dosing, evidence and sources (Community guide · Accessed 2026-09-30)

Source context — Basic Peptide Dosing Protocols: Promotional copied chart; no TP-5 route, formulation, citation, course length or personal outcome. Unit conversion is arithmetic only; not validated regimen or consensus. Exact post date not exposed in the opened view.

Source context — Thymopentin: dosing, evidence and sources: Commercial library with shop/app links; copied formal-disease figures marked unverified, not measured or firsthand community wellness doses. No independent effectiveness inferred.

Half-life, onset & duration

Felt onset	No firsthand onset estimate in these discussions. Questions about effects and proposed immune uses do not establish a response after hours, days or weeks.
Felt duration	The physician's claimed year without UTIs is secondhand, with no verified route or amount. It does not measure one-injection duration or persistence in the body.
Half-life	No measured clearance timeline in dosed people here. The roughly thirty-second figure describes degradation in a human-plasma laboratory sample, not human injection half-life.

Notes

A claimed year without UTIs is a second-hand outcome. The purchaser attributes this to their physician after a course, without independent follow-up, route or amount. It does not show how long one injection feels active, how long the peptide remains in the body, or what another person would experience. Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30)

No measured community human half-life. CalcMyPeptide calls it “minutes-class” without a measured human timeline on its page. Short plasma-breakdown language is not the same as measuring clearance after an injection. The laboratory origin of the 30-second figure is explained below. Thymopentin Dosing Guide (Community guide · Accessed 2026-09-30)

About 30 seconds in a human-plasma laboratory test. The 1985 paper reports rapid degradation by plasma enzymes. This is breakdown in a sample, not a concentration-time study in dosed people. Its route-and-rate potency comparisons concern animals and cannot supply a human injection amount or felt-effect window. Thymopentin: stability considerations and potency by various routes of administration (Official context · Accessed 2026-09-30)

Source context — Thymopentin Dosing Guide: Editorial calculator page, not firsthand report or human pharmacokinetic study; vague half-life heading supplies no method, population or route. Regulatory assertions not adopted.

Cycles people discuss

Three-month story	The purchaser relays a physician's three-month course without frequency or break details. It does not establish a repeat calendar.
Separate short-course charts	Older leaflet-style talk gives 5–10 days. Other thymic peptides' 10–20-day bioregulator cycles cannot automatically be assigned to TP-5.

Notes

Three months: the physician's reported course. The purchaser relays this course length but supplies no injection frequency or break schedule. It belongs to the physician story discussed above; it does not establish how often a course is repeated. Seeking advice on dosing/efficacy of Thymopentin injections (Community discussion · Accessed 2026-09-30)

Five to ten days: a separate older chart pattern. The original leaflet-style account describes short courses. It does not establish seasonal repetition. Ten-to-twenty-day bioregulator cycles and weeks-on/weeks-off language should not be assumed to describe TP-5 merely because other thymic peptides appear in similar stacks.

Stacks

No specific pairing established	TP-5 appears in multi-bioregulator discussion without a supported pairing or outcome. A proposed Epitalon/Thymogen/Vilon experiment concerns different compounds and supplies no TP-5 stack result.

Notes

Thymus-regrowth stacks are a different conversation. A LongeCity self-experiment outline combines Epitalon, Thymogen and Vilon. It is a proposed experiment, not a TP-5 outcome. It illustrates why thymic-peptide stack calendars cannot be copied across identities. How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Khavinson Peptides for Thymic Regrowth (Community opinion · Accessed 2026-09-30)

Stacks can obscure which compound did what. TP-5 appears in multi-bioregulator discussion without a supported pairing or stack result. Several simultaneous changes make both benefits and side effects harder to attribute; a favorable combination story cannot establish TP-5's contribution.

Source context — How to Plan and Carry Out a Simple Self-Experiment, a Single Person Trial of Khavinson Peptides for Thymic Regrowth: Adjacent-identity source used only to distinguish stacks; no TP-5 dose, efficacy, safety or cycle inferred. Proposal not completed outcome; instructions and sourcing content not reproduced.

Watch for

Immune and muscle-weakness concerns	A case report describes myasthenia gravis after repeated TP-5 courses, without establishing risk frequency. New swallowing/breathing difficulty or progressive muscle weakness needs medical assessment.
Product and injection problems	Allergy, unknown impurities, redness, itching, lumps and bruising are flagged. Mild-effect claims do not establish a vial's identity, sterility, tolerability or long-term safety.

Notes

Immune regulation is not a safety assurance. The autoimmune commenter urges physician supervision, despite their favorable interpretation. A clinical case report describes myasthenia gravis following repeated TP-5 courses in a cancer survivor. It raises a possible association with this autoimmune muscle-weakness condition; it does not establish the frequency of that risk. Peptides for autoimmune disease (Community opinion · Accessed 2026-09-30) · Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance (Official context · Accessed 2026-09-30)

Serious symptoms need medical care. Severe allergic symptoms, chest pain, neurological changes or uncontrolled blood pressure or glucose need real medical assessment. New swallowing or breathing difficulty and progressive muscle weakness are especially concerning; an immune-peptide discussion cannot explain them away. Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance (Official context · Accessed 2026-09-30)

Product uncertainty and injection reactions matter. Discussion flags allergy, unknown impurities, redness, itching, lumps and bruising. Long-term safety of unverified preparations remains uncertain. Commercial claims of mild effects do not establish the identity, sterility or tolerability of a particular vial.

Source context — Thymopentin-Induced Myasthenia Gravis: A Case Report Highlighting Clinical Vigilance: One clinical case; temporal association and authors' possible causal interpretation, not incidence or proof. Prior cancer/treatment and simultaneous MG care complicate attribution. Formal amounts and course kept out of community practical fields.

Full notes

Thymopentin, also called TP-5, is a synthetic thymic peptide discussed for immune support, recurring infections and immune regulation. The available conversations contain questions and second-hand claims rather than a clear firsthand benefit timeline. It is a different compound from Thymalin and Thymosin Alpha-1.

What Thymopentin is

TP-5 is a defined five-part peptide. Its five amino acids, the building blocks of a peptide, are abbreviated RKDVY. It copies positions 32–36 of the larger thymus hormone thymopoietin. The immune research concerns T cells, which help coordinate immune responses; it does not establish a general wellness reset. Official context Reddit r/Peptides
Similar names do not mean the same substance. Thymalin, thymulin, Thymogen and Thymosin Alpha-1 are separate identities. In the purchaser discussion, commenters switch between several of those names. Their experiences, amounts and courses cannot automatically answer a question about TP-5. Reddit r/Peptides Community
Injection talk needs a product and route. The purchaser described a physician-recommended product in China without stating an amount or injection route. Older research-chemical discussion names subcutaneous use, meaning under the skin. That does not identify the purchaser's preparation or make every TP-5 product interchangeable. Reddit r/Peptides Community

What people hope to get from it

Fewer recurring infections. The purchaser's interest began with a physician's reported experience with recurring urinary tract infections, or UTIs. This is an account of someone else's claimed benefit, not a demonstrated result from the person posting or evidence that TP-5 treats an active infection. Reddit r/Peptides
Immune regulation, rather than simply more activity. An autoimmune-thread commenter speculates that TP-5 may regulate an overactive response and cites an older study of myasthenia gravis, a condition causing muscle weakness. They do not report taking TP-5. Anti-aging also interests the purchaser, but neither discussion supplies a personal rejuvenation, energy or recovery result. Reddit r/Peptides Reddit r/Peptides

Doses people discuss

100–200 mcg per use, every three days: one promotional chart. PeptideBasicsDOTcom's Reddit table lists this amount, equivalent to 0.1–0.2 mg. It gives no TP-5 route, product, supporting source or personal outcome. This is a chart assertion, not a checked common dose or a daily total. Community guide
About 50 mg per injection: older product-chart talk. The older chart account pairs this with daily or every-other-day injections. Its product and exact route are unresolved. The microgram chart has a different origin; this large numerical disagreement does not establish a useful dose range. Community
50 mg three times weekly: a circulated historical-study figure. Peptide Corpus lists this under-the-skin HIV schedule as unverified imported information. Its origin is a disease-specific research claim, not a firsthand wellness report. The site's intravenous rheumatoid-arthritis figure is a separate route and context. Community guide

Half-life

No measured community human half-life. CalcMyPeptide calls it “minutes-class” without a measured human timeline on its page. Short plasma-breakdown language is not the same as measuring clearance after an injection. The laboratory origin of the 30-second figure is explained below. Community guide

When an effect starts

No firsthand onset estimate in these discussions. The purchaser asks what effects others feel; no visible personal post-use result answers that question. The autoimmune commenter discusses a possible use rather than a timed experience. Neither supplies a predictable response after hours, days or two weeks. Reddit r/Peptides Reddit r/Peptides

How long a benefit lasts

A claimed year without UTIs is a second-hand outcome. The purchaser attributes this to their physician after a course, without independent follow-up, route or amount. It does not show how long one injection feels active, how long the peptide remains in the body, or what another person would experience. Reddit r/Peptides

Courses and breaks

Three months: the physician's reported course. The purchaser relays this course length but supplies no injection frequency or break schedule. It belongs to the physician story discussed above; it does not establish how often a course is repeated. Reddit r/Peptides
Five to ten days: a separate older chart pattern. The original leaflet-style account describes short courses. It does not establish seasonal repetition. Ten-to-twenty-day bioregulator cycles and weeks-on/weeks-off language should not be assumed to describe TP-5 merely because other thymic peptides appear in similar stacks. Community

What to watch for

Immune regulation is not a safety assurance. The autoimmune commenter urges physician supervision, despite their favorable interpretation. A clinical case report describes myasthenia gravis following repeated TP-5 courses in a cancer survivor. It raises a possible association with this autoimmune muscle-weakness condition; it does not establish the frequency of that risk. Reddit r/Peptides Official context
Product uncertainty and injection reactions matter. Discussion flags allergy, unknown impurities, redness, itching, lumps and bruising. Long-term safety of unverified preparations remains uncertain. Commercial claims of mild effects do not establish the identity, sterility or tolerability of a particular vial. Community
Serious symptoms need medical care. Severe allergic symptoms, chest pain, neurological changes or uncontrolled blood pressure or glucose need real medical assessment. New swallowing or breathing difficulty and progressive muscle weakness are especially concerning; an immune-peptide discussion cannot explain them away. Community Official context

What the laboratory timing actually means

About 30 seconds in a human-plasma laboratory test. The 1985 paper reports rapid degradation by plasma enzymes. This is breakdown in a sample, not a concentration-time study in dosed people. Its route-and-rate potency comparisons concern animals and cannot supply a human injection amount or felt-effect window. Official context

From community discussion

The purchaser's own favorable report was about D-mannose. Their personal UTI-prevention account concerned that separate supplement, with missed doses mentioned in the conversation. It must not be counted as a successful TP-5 trial. No visible TP-5 nonresponse or adverse experience from that purchaser was found either. Reddit r/Peptides
Thymus-regrowth stacks are a different conversation. A LongeCity self-experiment outline combines Epitalon, Thymogen and Vilon. It is a proposed experiment, not a TP-5 outcome. It illustrates why thymic-peptide stack calendars cannot be copied across identities. LongeCity forum
Stacks can obscure which compound did what. TP-5 appears in multi-bioregulator discussion without a supported pairing or stack result. Several simultaneous changes make both benefits and side effects harder to attribute; a favorable combination story cannot establish TP-5's contribution. Community